Cumberland Pharmaceuticals Inc.
CPIX Healthcare Drug Manufacturers Specialty & Generic
Cumberland Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, up 17.6% from fiscal 2024.
- Revenue
- −98.5%
- EPS
- −480.0%
- Free cash flow
- −82.8%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow CPIX
Alert me
Cumberland Pharmaceuticals Inc. (CPIX) P/E ratio
Cumberland Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 5,556× (September 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CPIX Cumberland Pharmaceuticals Inc. | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| TLPH Talphera, Inc. compare | n/m |
| ORGO Organogenesis compare | n/m |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| INCR InterCure Ltd. compare | 6.2× |
| BGM BGM Group Ltd. compare | 148× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)